Heligenics
heligenics.com
Drug Discovery
Biologics & Biosimilars
Biotechnology
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$6M
5 rounds on record
Latest round
$2.6M
Venture round · Aug 2024 · 2 yr ago
Team
11-50
employees, estimated range
Grants
$1.2M
2 grants · CORDIS
Revenue
$1M
2024 · SEC Form D 0001833506-25-000003
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 1, 2025
Won a grant $808k · CORDIS
Aug 23, 2024
Raised a round Venture round $2.6M · SEC Form D
Feb 2, 2023
Won a grant $399k · CORDIS
Aug 23, 2022
New executive Martin Schiller, Executive Officer · SEC Form D
Jun 9, 2022
Raised a round Venture round $2.2M · SEC Form D
Mar 31, 2020
Raised a round Venture round $1.2M · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jan 2025 | $808k | — | CORDIS |
| Venture round | Aug 2024 | $2.6M | — | SEC Form D |
| Grant | Feb 2023 | $399k | — | CORDIS |
| Venture round | Jun 2022 | $2.2M | — | SEC Form D |
| Venture round | Mar 2020 | $1.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Heligenics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Lawrence LoomisExecutive Officer, DirectorSEC Form D
Martin SchillerExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
ABL Bio is a South Korean biotechnology company focused on developing innovative biologic drugs, with antibody, ADC and polynucleotide…
Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance.
High-throughput cell line development for biopharmaceuticals. DNA barcoding platform that screens thousands of CHO cell lines…
Leading the advancement of biologics for targeted immune regulation & restoration.
Find out more about Biodextris, your premier biologics development and manufacturing partner. Check out our cutting-edge solutions.
Visualize live cell function at scale with Pixel™: power cell biology discovery with insights on viability, morphology, ephys, & more.
People
Lawrence Loomis
Executive Officer, Director
Martin Schiller
Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Las Vegas
United States
HQ
10-50 est. staff
10530 Discovery Drive, Las Vegas, NV, 89135-3049, US
Financials
Est. Annual Revenue
$500k
2024
Total raised
$7.2M
Latest round
Grant
Funding rounds
5
Revenue
Estimate
Low-high range
Modelled from public signals, not audited accounts - read it as an order of magnitude.
| Year | Estimate | Low | High |
|---|---|---|---|
| 2019 | $500k | $1 | $1M |
| 2021 | $500k | $1 | $1M |
| 2024 | $500k | $1 | $1M |